Who are ACT-709478 for oral use's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lithium or Valproate with Aripiprazole, Rasagiline mesylate plus Mirapex, Aripiprazole 6-week group, Aripiprazole + desvenlafaxine succinate sustained release, omeprazole+domperidone SR, ropinirole/L-dopa.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/act-709478-for-oral-use.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ACT-709478 for oral use — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ACT-709478 for oral use (ACT-709478 for oral use) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine receptor antagonist. Area: Psychiatry.

phase 2 Dopamine receptor antagonist D2/D3 receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

ACT-709478 for oral use (ACT-709478 for oral use) — Idorsia Pharmaceuticals Ltd.. ACT-709478 is a selective dopamine receptor D2/D3 antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ACT-709478 for oral use TARGET	ACT-709478 for oral use	Idorsia Pharmaceuticals Ltd.	phase 2	Dopamine receptor antagonist	D2/D3 receptor
Lithium or Valproate with Aripiprazole	Lithium or Valproate with Aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic combined with mood stabilizers	Dopamine D2/D3 receptors, serotonin 5-HT1A receptor (aripiprazole); inositol monophosphatase, GSK-3 (lithium); histone deacetylase (valproate)
Rasagiline mesylate plus Mirapex	Rasagiline mesylate plus Mirapex	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor plus dopamine agonist combination	Monoamine oxidase B and dopamine D2/D3 receptors
Aripiprazole 6-week group	Aripiprazole 6-week group	Seoul National University Hospital	marketed	Atypical antipsychotic	Dopamine D2/D3 receptor (partial agonist); serotonin 5-HT1A receptor (partial agonist); serotonin 5-HT2A receptor (antagonist)
Aripiprazole + desvenlafaxine succinate sustained release	Aripiprazole + desvenlafaxine succinate sustained release	Pfizer	marketed	Atypical antipsychotic + serotonin-norepinephrine reuptake inhibitor (SNRI) combination	Dopamine D2/D3 receptors (aripiprazole); serotonin transporter (SERT) and norepinephrine transporter (NET) (desvenlafaxine)
omeprazole+domperidone SR	omeprazole+domperidone SR	Belarusian Medical Academy of Post-Graduate Education	marketed	Proton pump inhibitor + dopamine antagonist combination	H+/K+-ATPase (omeprazole); dopamine D2/D3 receptors (domperidone)
ropinirole/L-dopa	ropinirole/L-dopa	GlaxoSmithKline	marketed	Dopamine agonist and dopamine precursor combination	Dopamine D2/D3 receptors (ropinirole); dopamine synthesis pathway (L-dopa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine receptor antagonist class)

Idorsia Pharmaceuticals Ltd. · 1 drug in this class
Intec Pharma Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACT-709478 for oral use — Competitive Intelligence Brief. https://druglandscape.com/ci/act-709478-for-oral-use. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab